Accent Microcell Ltd. (ACCENTMIC)
SME CapPharma stocks · SME cap · NSE
Accent Microcell Ltd. manufactures pharmaceutical excipients, focusing on cellulose-based products like MCC, SMCC, and MCC Spheres. It operates two units (Pirana, Dahej SEZ) and exports to over 75 countries. The company caters to pharma, nutraceutical, food, dairy, and cosmetic industries, with a growing emphasis on premium product ranges.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, price trend supports entry, and recent execution is mixed.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Excellent · 77/100Rev +51% YoY · PAT +63% YoY · +51% QoQ · operating leverage · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹210 Cr | +51.1% | +51.1% |
| EBITDA | ₹33 Cr | +43.5% | +37.5% |
| Operating margin | 16.0% | -100 bps | -100 bps |
| PAT | ₹26 Cr | +62.5% | +44.4% |
| PAT margin | 12.4% | +15 bps | -57 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
FY26 revenue and PAT increased YoY, driven by higher export sales (63% of revenue) and a shift towards premium products. Unit 3 Phase 1 commercialization delayed to June 2026 due to regulatory approvals and monsoon, impacting immediate capacity expansion plans.
Management's repeated delays in Unit 3 Phase 1 commissioning, now expected June 2026, raise concerns about execution. While H2 FY26 saw a shift to higher-margin premium products and increased exports, reliance on trading volumes (25% of sales) to meet demand highlights current capacity constraints. Future growth hinges on timely Unit 3 ramp-up and successful commercialization of new pulp-based CMC/CCS.
Revenue by Geography (FY26)
Latest issuer-disclosed distribution across 2 reported categories.
Premium Product Focus
Substantial increase in premium range products (SMCC and Spheres) in H2 FY26. Phase 1 of Unit 3 will cater to premium excipient products.
Export Market Expansion
Export revenue increased from 53% to 63% of total sales, indicating strong international demand and market penetration.
Unit 3 Capacity Addition
Unit 3 Phase 1 will add 2,400 MT capacity for premium excipients (CCS, SSG, CMC). Phase 2 will add MCC capacity.
Proprietary Technology
Company claims to be India's first plant to make pulp-based CMC and process it forward for CCS, developed after 8 years of R&D.
Unit 3 Phase 1 (Premium Excipients)
Expected to go live by June 25th, 2026, after receiving GPCV and pollution control licenses. Total capacity of 2,400 MT for CCS, SSG, CMC.
Unit 3 Phase 2 (MCC)
Expected to go live in March 2027. Anticipated to achieve 75-80% capacity utilization from the first year onwards.
Unit 3 Phase 3-6
Land purchased for up to Phase 6. Phase 3 is an ongoing plan, tentatively expected to start in 2028, pending success of Phase 2.
Strong Order Book
Current MCC demand outlook is good, with roughly 4,000 metric tons of orders on hand for domestic and export markets.
Pricing Power
Nominal increase in raw material (wood pulp) cost has been completely passed on to customers.
Favorable Currency Devaluation
With exports being 3x the amount of imports, currency devaluation provides a positive financial benefit.
Unit 3 Commissioning Delays
Phase 1 delay primarily due to two back-to-back abnormal monsoons and pending regulatory approvals (licensing work, CTO, CCA).
Reliance on Trading Volumes
Roughly 25-30% of total sales volumes were from traded products in FY26, with trading margins of 5-6%.
Execution Risk for Unit 3
Repeated delays in Unit 3 Phase 1 commissioning, initially October 2025, then April 2026, now June 2026, raise concerns about project execution.
Regulatory Approval Uncertainty
Management states that giving exact timelines for Unit 3 commercialization is technically not possible due to events beyond their control.
Competitive Intensity
A competitor (Sigachi) is expanding MCC capacity by 18,000 MT in Dahej, potentially increasing market competition.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
The company reports for the full financial year and half-year, comparing current year performance to the previous financial year, indicating a focus on annual trends rather than sequential momentum.
Export Revenue Contribution
ODAC exports, it's roughly, say, around 63%, which was, 53% last year.
New Product Launches
MCC spheres that we have started exporting into global markets and in domestic market as well. Croscarmellose sodium, Magnesium Stearate, and Cellulose are existing products.
Regulatory Approvals
Required certification in place to export to various countries, namely XPAC, GMP, ISO, FSSI, HSCCP, USDMF. US DMF is applicable for excipient companies.
Gross Profit Percentage
Gross profit percentage is around 38%.
Focus on Blended Margins
Management advises focusing on blended EBITDA percentage rather than product-wise or category-wise profit margins due to trading activities.
Reduced Trading Post-Phase 2
Trading volumes are expected to reduce substantially post-commercialization of Unit 3 Phase 2.
Funding Future Phases
Internal accruals are expected to suffice for future phases (Phase 3-6), with no further debt requirements foreseen as of now.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Unit 3 Phase 1 Commercialization | Delayed to June 2026. | Actual start date of commercial production and initial ramp-up of premium excipient volumes. |
| Premium Product Contribution | 13% of revenue (FY25-26). | Increase to 16-17% in FY27H2, indicating successful market penetration of higher-margin products. |
| Trading Volumes | 25-30% of total sales in FY26. | Substantial reduction post Unit 3 Phase 2 commissioning (expected March 2027), improving overall profitability. |
| EBITDA Margins | Implied ~16% (from 38% GP and 5-6% trading margins). | Increase by 2-3 percentage points as premium product mix rises and trading volumes decrease. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
67Bullishfull bull SMA stack · SMA20 +15.8% / mo · RSI overbought · MACD − · near 52W high · sector +2.2pp vs Nifty (3M)
Technical chart
ACCENTMICdaily · 1Y · AUTO+81.7%Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 71. Wait for confirmation.
- Price > SMA20 > SMA50 > SMA200 — full bullish stack.
- SMA20 rising (~13.6% over last month) — short-term momentum positive.
- RSI(14) at 71 — overbought zone; risk of mean reversion.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 3% of 52-week high — testing resistance.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 58 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 58 · FAIR VALUE · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 24.9%.
- Growth contributes 22/25 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: -2 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 83rd percentile of the scored universe and 76th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter pledge is zero. Key concern: Promoter holding fell 2.4%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 76th pctile, median 70 · SME: 97th pctile, median 64
3 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸5 years of positive FCF.
- ▸Debt/equity is 0.00.
- ▸ROCE is 24.9%.
Trust risks
- ▸Promoter holding fell 2.4%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 33.80
- P/B
- 5.37
- EV/EBITDA
- 23.92
- Market Cap
- 1482.00Cr
Profitability
- ROE
- 18.60%
- ROCE
- 24.90%
- ROA
- 13.66%
- Dividend Y
- 0.16%
Growth (CAGR)
- Revenue 5Y
- 21.00%
- EPS 5Y
- 54.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- 53.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 57.00×
- Altman Z
- 9.07
- Book Value
- 115.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 5/5
- OCF
- 19.00 Cr
- EPS TTM
- 18.28
Shareholding
- Promoter Hold
- 53.02%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 99%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.